Anita Sulibhavi1, Matthew L Rohlfing2, Scharukh M Jalisi3, David B McAneny4, Gerard M Doherty5, Michael F Holick6, J Pieter Noordzij7. 1. Department of Otolaryngology-Head & Neck Surgery, Boston Medical Center, Boston, MA, United States of America. Electronic address: asulibha@bu.edu. 2. Department of Otolaryngology-Head & Neck Surgery, Boston Medical Center, Boston, MA, United States of America. Electronic address: Matthew.rohlfing@bmc.org. 3. Department of Otolaryngology - Head & Neck Surgery, Beth Israel Deaconess Medical Center, Boston, MA. Electronic address: sjalisi@bidmc.harvard.edu. 4. Department of Surgery, Boston Medical Center, Boston, MA, United States of America. Electronic address: David.McAneny@bmc.org. 5. Department of Surgery, Brigham and Women's Medical Center, Boston, MA, United States of America. Electronic address: gmdoherty@partners.org. 6. Division of Endocrinology, Department of Medicine, Boston Medical Center, Boston, MA, United States of America. Electronic address: Michael.Holick@bmc.org. 7. Department of Otolaryngology-Head & Neck Surgery, Boston Medical Center, Boston, MA, United States of America. Electronic address: Pieter.Noordzij@bmc.org.
Abstract
PURPOSE: As imaging technology improves and more thyroid nodules and malignancies are identified, it is important to recognize factors associated with malignancy and poor prognosis. Vitamin D has proven useful as a prognostic tool for other cancers and may be similarly useful in thyroid cancer. This study explores the relationship of Vitamin D to papillary thyroid carcinoma stage while accounting for socioeconomic covariates. MATERIALS AND METHODS: The medical records of all patients who underwent thyroidectomy at one institution between 2000 and 2015 were reviewed. Subjects with non-papillary thyroid cancer pathology, prior malignancy, and without Vitamin D levels were excluded. The remaining 334 patient records were examined for cancer stage, Vitamin D levels, Vitamin D deficiency listed in history, and demographic and comorbid factors. RESULTS: Vitamin D laboratory values showed no significant relationship to cancer stage (p = 0.871), but patients with Vitamin D deficiency documented in the medical record were more likely to have advanced disease (28.6% versus 14.7%; p = 0.028). The patients with documented Vitamin D deficiency also had lower 25-hydroxyvitamin D nadirs (21.5 ng/mL versus 26.5 ng/mL, p = 0.008) and were more likely to be on Vitamin D supplementation (92.6% versus 41.8%, p < 0.001). CONCLUSIONS: The results suggest that Vitamin D deficiency may have value as a negative prognostic indicator in papillary thyroid cancer and that pre-operative laboratory evaluation may be less useful. This is important because Vitamin D deficiency is modifiable. While different racial subgroups had different rates of Vitamin D deficiency, neither race nor socioeconomic status showed correlation with cancer stage.
PURPOSE: As imaging technology improves and more thyroid nodules and malignancies are identified, it is important to recognize factors associated with malignancy and poor prognosis. Vitamin D has proven useful as a prognostic tool for other cancers and may be similarly useful in thyroid cancer. This study explores the relationship of Vitamin D to papillary thyroid carcinoma stage while accounting for socioeconomic covariates. MATERIALS AND METHODS: The medical records of all patients who underwent thyroidectomy at one institution between 2000 and 2015 were reviewed. Subjects with non-papillary thyroid cancer pathology, prior malignancy, and without Vitamin D levels were excluded. The remaining 334 patient records were examined for cancer stage, Vitamin D levels, Vitamin D deficiency listed in history, and demographic and comorbid factors. RESULTS:Vitamin D laboratory values showed no significant relationship to cancer stage (p = 0.871), but patients with Vitamin D deficiency documented in the medical record were more likely to have advanced disease (28.6% versus 14.7%; p = 0.028). The patients with documented Vitamin D deficiency also had lower 25-hydroxyvitamin D nadirs (21.5 ng/mL versus 26.5 ng/mL, p = 0.008) and were more likely to be on Vitamin D supplementation (92.6% versus 41.8%, p < 0.001). CONCLUSIONS: The results suggest that Vitamin D deficiency may have value as a negative prognostic indicator in papillary thyroid cancer and that pre-operative laboratory evaluation may be less useful. This is important because Vitamin D deficiency is modifiable. While different racial subgroups had different rates of Vitamin D deficiency, neither race nor socioeconomic status showed correlation with cancer stage.
Authors: A M Cocolos; S Vladoiu; A Caragheorgheopol; A M Ghemigian; D Ioachim; C Poiana Journal: Acta Endocrinol (Buchar) Date: 2022 Apr-Jun Impact factor: 1.104
Authors: Andra-Maria Cocolos; Andrei Muresan; Andra Caragheorgheopol; Mircea Ghemigian; Dumitru Ioachim; Catalina Poiana Journal: In Vivo Date: 2022 Sep-Oct Impact factor: 2.406